Depressive illness has been shown to be associated with
|
|
- Vivian Shelton
- 6 years ago
- Views:
Transcription
1 Effect on Disability Outcomes of a Depression Relapse Prevention Program MICHAEL VON KORFF, SCD, WAYNE KATON MD, CAROLYN RUTTER, PHD, EVETTE LUDMAN, PHD, GREG SIMON, MD, MPH, ELIZABETH LIN, MD, MPH, AND TERRY BUSH, PHD Objective: This report evaluates the effects of a depression relapse prevention program on disability outcomes among patients treated for depression at high risk for relapse. Materials and Methods: Primary care patients initiating antidepressant treatment for depression were assessed 6 to 8 weeks after the initial prescription. Patients responding to initial treatment but at high risk for relapse were randomized to usual care or a relapse prevention intervention (N 386). The 12-month relapse prevention program included systematic patient education, two psycho-educational visits with a depression prevention specialist, shared decisionmaking regarding maintenance pharmacotherapy, and ongoing monitoring of medication adherence and depressive symptoms via telephone and mail. Disability outcomes were assessed via blinded telephone assessments at 3, 6, 9, and 12 months using SF-36 and Sheehan Disability scales. Results: Usual care patients and relapse prevention program patients had high rates of use of maintenance pharmacotherapy. Both relapse prevention and usual care patients showed improved functioning over the 12-month follow-up period. One of the three disability measures (the SF-36 Social Function scale) showed a significant intervention effect because of continuing improvement at 9 and 12 month follow-up, whereas the Sheehan Disability Scale showed a nonsignificant trend toward greater improvements in disability among relapse prevention patients than among usual care controls. Conclusions: Moderate effects of a relapse prevention intervention on depressive symptoms were associated with modest and variable effects on disability outcomes. Inconsistent effects of the intervention for disability outcomes may be because of the high rates of maintenance pharmacotherapy among usual care patients, relatively mild levels of depressive symptoms among both intervention and control patients at baseline, the absence of a specific relapse prevention effect of the intervention, and the resultant modest differences in depressive symptoms between intervention and control patients in this trial. Key words: depression, disability, randomized trial, relapse prevention. GHC Group Health Cooperative; SCID Structured Clinical Interview for DSM-IV. INTRODUCTION Depressive illness has been shown to be associated with significant social role disability in a wide range of populations (1 3). The levels of disability among depressed patients are as great as or greater than among patients with major physical diseases (1). Disability improves significantly as depression improves while chronically depressed patients often experience poor disability outcomes (4, 5). A series of randomized controlled trials has now shown that enhanced care of major depression in the primary care setting can improve disability outcomes (6 10). Recently, Wells et al. reported that enhanced care of major depression increased retention in employment at 1-year follow-up (10). However, a few trials of enhanced depression care have not found improved disability outcomes even though some improvement in symptoms was reported (11,12). These negative results may be because of use of disability measures that are insensitive to change in functional status in nongeriatric depressed populations (eg, the SF-12 physical function scale) and to small effect sizes for depressive symptom outcomes caused by significant numbers of usual care patients who were adequately treated. Overall, experimental studies now support a conclusion that enhanced acute phase treatment of major Center for Health Studies (M.V.K., C.R., E.L., G.S., E.L., T.B.), Group Health Cooperative, Seattle, WA and Department of Psychiatry and Behavioral Sciences (W.K.), University of Washington. Address correspondence and reprint requests to Michael Von Korff, ScDPh, Center for Health Studies, Group Health Cooperative, 1730 Minor Avenue, Suite 1600, Seattle, WA Vonkorff.M@GHC.ORG Received for publication April 25, 2003; revision received July 15, This research was supported by NIH grant MH41739 from the National Institute of Mental Health. DOI: /01.PSY C depression in the primary care setting improves disability outcomes. Among primary care patients with major depression, recurrences are common (13). Sustained treatment of severely depressed patients in continuation and maintenance phases after effective acute phase treatment has been shown to reduce relapse rates (14 17). However, little is known about the effects of sustained treatment on disability outcomes, particularly among the less severely depressed patients treated in primary care settings. In earlier articles, we described a relapse prevention program for primary care patients recovered from a depressive episode who remained at high risk for relapse (18). This relapse prevention program improved medication adherence and resulted in modest improvements in depressive symptoms at 9- and 12-month follow-up relative to a care as usual control group (19,20). The objective of this article is to assess the effects of this program on disability outcomes. MATERIALS AND METHODS The intervention, methods, and effects on depression outcomes of this study are fully reported in previous articles (18 20). Participants were recruited from four large primary care clinics of Group Health Cooperative (GHC), a group model health maintenance organization serving approximately 400,000 persons in Washington State. Computerized pharmacy and visit registration records were used to identify all patients receiving a new antidepressant prescription from a primary care physician associated with a visit diagnosis of a depressive disorder (including physician diagnoses of major depressive episode, dysthymia, and depressive disorder NOS). A new prescription was defined by an interval of at least 120 days since last use of an antidepressant (based on prescription date and intended duration of use). An invitation letter was mailed to all potentially eligible patients approximately 1 month after the initial prescription. Potential participants were then contacted by telephone 6 to 8 weeks after the initial prescription. After a documented oral consent procedure, participants completed a telephone screening assessment including the current and past depression modules of the Structured Clinical Interview for DSM-IV (or SCID) (21). Patients were invited to participate in an in-person baseline assessment based on the following criteria: significant residual symptoms (ie, four or more of the nine 938 Psychosomatic Medicine 65: (2003) /03/ Copyright 2003 by the American Psychosomatic Society
2 DEPRESSION RELAPSE PREVENTION PROGRAM DSM-IV depression criteria), current dysthymia (ie, depressive symptoms present for 2 years or more), or history of recurrent depression (ie, 2 or more previous depressive episodes). The baseline assessment typically occurred approximately 2 months after the primary care visit that initiated depression treatment. The in-person baseline assessment included a 20-item depression scale extracted from the SCL-90 (22). Clinical eligibility criteria included remission of the index depressive episode (defined as either less than four of the nine DSM-IV depression criteria or four DSM-IV depression criteria with SCL depression score less than 1.0) and high risk for relapse (defined as a history of 3 or more lifetime depressive episodes or a history of dysthymic disorder). Criteria for exclusion were: score of 2 or more on the CAGE alcohol questionnaire, plans to disenroll from GHC within 12 months, recent use of mood stabilizer or antipsychotic medication, pregnant or nursing, and current medication management by a psychiatrist. After a full explanation of study procedures, written informed consent was obtained from all participants. Patients assigned to the usual care group could receive any services normally available inside or outside of GHC including referral to specialty mental health care. No additional services were provided, but no services usually available were limited or withheld. The relapse prevention program (18) was a multifaceted intervention including the following components: (1) an educational book and videotape regarding effective management of depression, with a focus on chronic or recurrent depression; (2) two in-person visits with a depression prevention specialist, including shared decision-making regarding maintenance antidepressant treatment; (3) three scheduled telephone monitoring contacts (2, 5, and 9 months after enrollment) including monitoring of depressive symptoms and treatment adherence; and (4) four personalized mailings (3, 6, 10, and 12 months after enrollment) for continued monitoring of depressive symptoms and treatment adherence. Depression prevention specialists communicated regularly with treating primary care physicians regarding treatment discontinuation, signs of depressive relapse, or other situations requiring clinical attention (eg, intolerable medication side effects). Treating primary care clinicians remained responsible for all pharmacotherapy decisions. If needed, patients were referred for in-person consultation with an on-site liaison psychiatrist or for ongoing treatment in GHC s specialty behavioral health clinic. Each depression prevention specialist met with a supervising psychiatrist (in-person or by telephone) for 15 to 30 minutes each week. The baseline interview occurred immediately before randomization. Clinical outcomes were subsequently assessed via blinded telephone interviews 3, 6, 9, and 12 months after randomization. These interviews included repeat administration of the SCL-90 depression scale (the primary outcome measure). Disability outcomes were measured by the Sheehan Disability Scale (23) and by the SF-36 social function and role emotional scales (24). The Sheehan Disability Scale consists of three 0 to 10 ratings of the extent that illness interferences with work, family, and social life. The SF-36 social function scale asks patients to rate the degree to which physical health or emotional problems interfered with social activities with family, friends, neighbors, or groups, and the amount of time physical health or emotional problems interfered with social activities like visiting with friends and close relatives. The role emotional scale asks about the amount of time the patient: decreased work and other activities because of emotional problems; accomplished less than they would like; and performed work or other activities less carefully than usual. We assessed the effect of time and intervention on disability outcomes using linear regression models. The regression models were used to estimate the effect of treatment while adjusting for age, sex, physical co-morbidity [Chronic Disease Score (25, 26)], neuroticism (NEO) (27), and baseline SCL score. These models accounted for correlation in longitudinal assessments across the four follow-up times using an unstructured correlation matrix, with estimation performed using generalized estimating equations. The regression models included an overall effect of intervention, a linear time effect, and an interaction between time and intervention (28 30). We found differences in follow-up rates for intervention and usual care groups, with somewhat higher rates of follow-up among intervention than usual care patients. Across all interviews, 10.1% of follow-up interviews were missing: 6.2% in the intervention group and 12.5% in the control group. The proportion of interviews that were missing increased over the follow-up period, with 10.3% of Psychosomatic Medicine 65: (2003) the intervention group and 20.8% of the usual care group missing interviews at 12 months. We assumed that missing data depended only on observed outcomes and used observed data to account for differential drop-out via multiple imputation with propensity-score matching of missing to observed cases (31). We adjusted only for unit nonresponse (ie, missing interviews) because there was very little item nonresponse. Propensity scores were estimated separately for each time point using logistic regression models with completely observed baseline covariates (randomization group, married, live alone, single parent, college graduate, panic attack in the past 2 weeks, self-rated health, self-reported high stress, satisfaction with HMO care, physical co-morbidity (CDS), and baseline SCL). Propensity score matching was stratified by intervention group, quartile of propensity score, and interview. We imputed data for entire cases, but separately for each missed follow-up time, thereby incorporating the cross-sectional correlation of outcome and covariate data, but ignoring between time correlation of outcomes. Probabilities of nonresponse based on this set of variables achieved good prediction of nonresponse status at each follow-up. For example, at the 12 month follow-up, the estimated probability of nonresponse exceeded 25% for 13% of subjects actually interviewed versus 40% of subjects who were missing. We report analyses for both the observed data and the observed data augmented with imputed values for persons with missing observations at follow-up. The observed and missing results were quite similar for disability outcomes. RESULTS In the study participation, a total of 386 patients were enrolled in the randomized trial (194 assigned to the relapse prevention program and 192 to usual care). Of this number, 315 (82%) completed all blinded follow-up assessments and 377 (98%) remained enrolled in GHC throughout the follow-up period. The proportion of patients completing all followup assessments was 88% (170/194) in the intervention group compared with 76% (145/192) in the usual care group ( , p 0.002). Those completing all follow-up assessments also had significantly lower SCL depression scores at baseline (mean 0.82, 0.36 vs. mean 0.92, 0.38; t 2.15, df 384, p 0.03). Participation in blinded follow-up assessments was not significantly associated with age or sex. Across the 14 variables examined, there was only one significant difference in participant characteristics between the intervention and control groups. Usual care patients were somewhat more likely to have met criteria for major depression within the previous year (Table 1). The baseline SCL score in both the intervention and control groups was approximately 0.84, indicating mild depressive symptoms as an SCL score of 0.5 or less indicates remission. While patients enrolled in this relapse prevention trial were substantially improved subsequent to treatment, and none met criteria for current major depression, the typical study participant continued to have mild to moderate depressive symptoms. Threequarters had a previous history of three or more depressive episodes, and approximately half had a history of dysthymia. Thus, the enrolled patients typically had a history of recurrent or chronic depression, and most continued to have mild depressive symptoms when enrolled. More than 80% were on antidepressant medication at the outset of the study. As reported previously (19), the proportion of usual care patients continuing antidepressant medication in the 9- to 12-month follow-up period was 50% in the usual care group compared with 63% in the intervention group. In the usual care group, the mean SCL score was 0.84 ( 0.35) at 939
3 M. VON KORFF et al. TABLE 1. Demographic and Clinical Characteristics of Depressed Patients Relapse Prevention Intervention N 195 Usual Care Control N 192 * p.01 Age, mean % Female % With 1 year of college % Employed full-time or part-time % White % Married SCL, depression, mean Chronic disease score, mean NEO, neuroticism, mean Recurrent depression (3 episodes) % Of major depression within past 2 years* % With dysthymia % Comorbid panic % On antidepressant medications at baseline baseline, 0.79 (0.47) at 3 months, 0.78 (0.51) at 6 months, 0.86 (0.57) at 9 months, and 0.74 (0.54) at 12 months. In contrast, in the intervention group, the mean SCL score decreased from 0.83 ( 0.39) at baseline to 0.75 (0.55) at 3 months, 0.74 (0.54) at 6 months, 0.69 (0.56) at 9 months, and 0.65 (0.51) at 12 months. Across the 12-month follow-up period, mean SCL depression score was somewhat lower in the intervention group (mean difference 0.08, p 0.04). As shown in Figure 1 and Table 2, intervention patients showed more favorable outcomes for the SF-36 Social Function scale than did usual care patients. Note that a higher score on this scale indicates lower levels of disability. The two groups showed equal improvement in disability from baseline to 6 months. After 6 months, the intervention group showed further improvements in social function scores, whereas the usual care controls showed no additional improvement in disability status on this measure after 6 months. After controlling for covariates, the time by intervention effect was statistically significant (p 0.05). The results for the role emotional scale of the SF-36 were similar in one respect and different in another. Both intervention and usual care patients showed improvements in disability status over time (p 0.01), after controlling for covariates (Table 3). However, intervention patients did not show significantly better disability outcomes than usual care patients on this scale as assessed by the time by intervention interaction term (p 0.78). For the Sheehan Disability Scale, both intervention and usual care patients tended to show improvement in disability over time (Table 4). While the time by intervention interaction effect was nonsignificant (p 0.14), the intervention patients tended to show greater improvements in disability on this measure than patients receiving care as usual. DISCUSSION This study assessed whether a low-intensity relapse prevention program resulted in better disability outcomes than Usual Care. The results for disability outcomes were mixed. Figure 1. SF-36 Social Function outcomes for relapse prevention program (RPP) patients compared with usual care control group patients (observed data without imputation). 940 Psychosomatic Medicine 65: (2003)
4 DEPRESSION RELAPSE PREVENTION PROGRAM TABLE 2. SF-36 Social Function Month N Usual care Relapse prevention Effects for imputed data* Estimate t statistic p value Intervention 0.27 ( 1.42) Time 0.66 ( 0.48) Intervention time 1.31 ( 0.66) * Adjusted for age, sex, chronic disease score, neuroticism, and baseline SCL score. TABLE 3. SF-36 Role Emotional Month N Usual care Relapse prevention Effects for imputed data* Estimate t statistic p value Intervention 1.52 ( 2.21) Time 2.51 ( 0.88) Intervention time 0.32 ( 1.16) * Adjusted for age, sex, chronic disease score, neuroticism, and baseline SCL score. One of three disability measures (the SF-36 Social Function scale) showed a significant intervention effect due to continuing improvement at 9 and 12 month follow-up, while the Sheehan Disability Scale showed a nonsignificant trend toward greater improvements in disability among relapse prevention patients than among usual care controls. Both the intervention and control group patients had, on average, only moderate levels of depressive symptoms at baseline, leaving only limited room for subsequent improvement in depressive symptom levels. The most severely depressed primary care patients, those who continued to have moderate to severe depressive symptoms when screened for enrollment, were not eligible for this relapse prevention study. In addition, a large percentage of the usual care patients continued to receive antidepressant treatment at long-term follow-up. Because many control patients continued to use antidepressant medication, the observed effect of the relapse Psychosomatic Medicine 65: (2003) prevention intervention on depressive symptoms may have been mitigated relative to a design in which the control group received no treatment or a placebo. While the intervention did produce a modest beneficial effect on depressive symptoms, the intervention did not result in a difference in relapse rates over the 1-year follow-up period. We believe the variable and modest effects on disability outcomes reflect the modest effects on depressive symptoms. In previous acute depression treatment trials, the magnitude of the effect on disability outcomes has been in proportion to the magnitude of the effect on depressive symptoms. In this trial, the lack of a relapse prevention effect, the low baseline levels of depressive symptoms, and the higher than expected rates of long-term antidepressant therapy in the usual care control group appear to have resulted in both a modest effect on depressive symptoms and a correspondingly modest and variable effect on disability outcomes. In previous acute phase depression treatment trials, 941
5 M. VON KORFF et al. TABLE 4. Sheehan Disability Score Month N Usual care Relapse prevention Effects for imputed data* Estimate t statistic p value Intervention 0.15 ( 0.17) Time 0.06 ( 0.06) Intervention time 0.12 ( 0.08) * Adjusted for age, sex, chronic disease score, neuroticism, and baseline SCL score. effect sizes for disability outcomes have tended to be smaller than effects sizes for depressive symptom outcomes. In light of the modest effect of the intervention on depressive symptoms, the results for disability outcomes appear to be in keeping with the results of previous intervention trials, which have also reported mixed results for disability outcomes across trials and measures. Our results suggest avenues for future research on the effects of relapse prevention interventions on disability outcomes. It is important to note that the effect of the intervention was through enhancing control of depressive symptoms rather than through prevention of relapse per se. If active follow-up support were targeted to patients unlikely to continue antidepressant treatment, then effects of the intervention on depression and disability outcomes might be greater. Similarly, targeting patients with moderate to severe residual symptoms, as opposed to the patients enrolled in this study with generally mild depressive symptoms, might increase the magnitude of the effect of a relapse prevention intervention relative to care as usual. Because disability outcomes continued to show improvement over the 1-year follow-up for both intervention and control patients, it suggests that recovery from a major depressive episode in this population of patients at high risk for relapse is a gradual process. Approximately one-third of the intervention and control patients experienced a major depressive episode during the 1-year follow-up (19), although these episodes were typically brief. The intervention tested here did not reduce the frequency of these recurrences, perhaps because of the patient population targeted, the intensity of the intervention, and/or the high rates of antidepressant treatment in the usual care control group. There is a need for practical approaches to active follow-up of high-risk patients recovering from major depressive episode that can prevent relapse, achieve optimal control of residual symptoms, and thereby achieve maximal restoration of functioning in work, family, and social life. The results of this study suggest that further research is needed on effective ways of targeting and sustaining treatment for depressed patients at high risk for relapse. REFERENCES 1. Wells KB, Golding JM, Burnham MA. Psychiatric disorder and limitations in physical functioning in a sample of the Los Angeles general population. Am J Psychiatry 1988;145: Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. J Am Med Assoc 1989;262: Ormel J, Von Korff M, Ustun TB, et al. Common mental disorders and disability: a strong and cross-culturally consistent relationship. Results from the WHO Collaborative Study. J Am Med Assoc 1994;272: Von Korff M, Ormel J, Katon W, et al. Disability and depression in medical patients: a longitudinal analysis. Arch Gen Psychiatry 1992;49: Ormel J, Von Korff M, Van Den Brink W, et al. Depression, anxiety and disability show synchrony of change: a 3 1/2 year longitudinal study in primary care. Am J Public Health 1993;83: Coulehan JL, Schulberg HC, Block MR, et al. Treating depressed primary care patients improves their physical, mental, and social functioning. Arch Intern Med 1997;157: Katzelnick DJ, Simon GE, Pearson, et al. Randomized trial of a depression management program in high utilizers of medical care. Arch Fam Med 2000;9: Lin EHB, Von Korff M, Russo J, et al. Can depression treatment in primary care reduce disability? A stepped care approach. Arch Fam Med 2000;9: Rost KM, Nutting P, Smith J, et al. Improving depression outcomes in community primary care practice: A randomized trial. J Gen Intern Med 2001;16: Wells KB, Sherbourne C, Schoenbaum M, et al. Impact of Disseminating Quality Improvement Programs for Depression in Managed Primary Care: A Randomized Controlled Trial. JAMA 2000;283: Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med 2000;9: Simon G, Katon W, Von Korff M, et al. Impact of improved depression treatment in primary care on daily functioning and disability. Psychol Med 1998;28: Lin E, Katon W, VonKorff M, et al. Relapse and recurrence of depression in primary care: Rate and clinical predictors. Arch Fam Med 1998;7: Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for mainte- 942 Psychosomatic Medicine 65: (2003)
6 DEPRESSION RELAPSE PREVENTION PROGRAM nance therapies in recurrent depression. Arch Gen Psychiatry 1990;47: Paykel E, Scott J, Teasdale J, et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999;56: Fava G, Rafanelli C, Grandi S, et al. Six-year outcome for cognitivebehavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998;155: Jarrett R, Kraft D, Doyle J, et al. Preventing recurrent depression using cognitive therapy with and without a continuation phase. Arch Gen Psychiatry 2001;58: Ludman E, Von Korff M, Katon W, et al. The design, implementation, and acceptance of a primary care based intervention to prevent depression relapse. Int J Psychiatry Med 2000;30: Katon W, Rutter C, Ludman E, et al. A randomized trial of relapse prevention of depression in primary care. Arch Gen Psychiatry 2001;58: Ludman E, Katon W, Bush T, et al. Behavioral factors associated with symptom outcomes in a primary care-based depression prevention intervention trial. Psychol Med 2003;33: First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinician Version. Washington: American Psychiatric Press; Derogatis L, Rickels K, Uhlenhuth EH, et al. The Hopkins Symptom Checklist: A measure of primary symptom dimensions. In: Pichot P, ed. Psychological Measurements in Psychopharmacology: Problems in Psychopharmacology. Basel, Switzerland: Kargerman; 1974: Leon AC, Shear MK, Portera L, et al. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 1992;27(2): Gandek B, Ware JE Jr, Aaronson NK, et al. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment J Clin Epidemiol 1998;51(11): VonKorff M, Wagner E, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45: Clark D, VonKorff M, Saunders K, et al. A Chronic Disease Score with empirically derived weights. Med Care 1995;33: Costa PT and McCrae RR. The NEO Personality Inventory Manual. Odessa, Florida: Psychological Assessment Resources; SAS/Statistics Software. Changes and Enhancements. SAS Technical Report Release. Cary, NC: SAS Institute; Singer JD. Using SAS PROC MIXED to fit multi-levl models, hierarchical models, and individual growth models. J Educ Behav Stats 1998; 24: Wolfinger R, and O Connell M. Generalized linear mixed models: a pseudo-likelihood approach. J Stat Comput Simulation 1993;43: Lavori PW, Dawson R, Shera D. A multiple imputation strategy for clinical trials with truncation of patient data. Stat Med 1995;14: Psychosomatic Medicine 65: (2003) 943
ORIGINAL ARTICLE. A Randomized Trial of Relapse Prevention of Depression in Primary Care
ORIGINAL ARTICLE A Randomized Trial of Relapse Prevention of Depression in Primary Care Wayne Katon, MD; Carolyn Rutter, PhD; Evette J. Ludman, PhD; Michael Von Korff, ScD; Elizabeth Lin, MD, MPH; Greg
More informationLong-Term Effects on Medical Costs of Improving Depression Outcomes in Patients With Depression and Diabetes
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Long-Term Effects on Medical Costs of Improving Depression Outcomes in Patients With Depression and Diabetes WAYNE J. KATON, MD 1 JOAN
More informationDepressive disorders are common in primary care,
Do Clinician and Patient Adherence Predict Outcome in a Depression Disease Management Program? Catherine J. Datto, MD, Richard Thompson, PhD, David Horowitz, MD, Maureen Disbot, RN, Hillary Bogner, MD,
More informationDepression & Diabetes: Pathways and TeamCare Studies
Depression & Diabetes: Pathways and TeamCare Studies Wayne Katon, MD 1 Mike VonKorff, ScD 2 Elizabeth Lin, MD, MPH 2 Paul Ciechanowski, MD, MPH 1 Evette Ludman, PhD 2 Joan Russo, PhD 1 Carolyn Rutter,
More informationA COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY
A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY Lingqi Tang 1, Thomas R. Belin 2, and Juwon Song 2 1 Center for Health Services Research,
More informationDepression in Chronic Physical Health Problems FULL GUIDELINE 1
O Connor 2005 U.S.A. Sertraline Placebo Study design data source Patients who were hospitalised for acute coronary syndromes and who met the APA s DSMIV criteria for major depressive disorder (MDD). :
More informationImplementing and Improving Depression Screenings in the Primary Care Setting. Janet Tennison, PhD, MSW, LCSW Behavioral Health Project Manager
Implementing and Improving Depression Screenings in the Primary Care Setting Janet Tennison, PhD, MSW, LCSW Behavioral Health Project Manager Today s Objectives Participants will: Increase understanding
More informationAge of Depressed Patient Does Not Affect Clinical Outcome in Collaborative Care Management
CLINICAL FOCUS: ADHD, DEPRESSION, PAIN, AND NEUROLOGICAL DISORDERS Age of Depressed Patient Does Not Affect Clinical Outcome in Collaborative Care Management DOI: 10.3810/pgm.2011.09.2467 Kurt B. Angstman,
More informationQuality ID #411 (NQF 0711): Depression Remission at Six Months National Quality Strategy Domain: Effective Clinical Care
Quality ID #411 (NQF 0711): Depression Remission at Six Months National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
More informationThe American healthcare system, particularly the managed
REPORTS Collaborative Care and Motivational Interviewing: Improving Depression Outcomes Through Patient Empowerment Interventions Bill Anderson, PharmD The American healthcare system, particularly the
More informationThe Relationship Between Suicide Ideation and Late-Life Depression
University of Massachusetts Boston From the SelectedWorks of Steven D Vannoy Winter 2007 The Relationship Between Suicide Ideation and Late-Life Depression Steven D Vannoy, University of Washington Paul
More informationThe Effect of Structured Relapse Prevention Planning on Attitudes to Recovery from Depression: a review of the literature and programme planning
Volume 2: Number 1 (Winter 2005) ISSN 1743-1611 (Online) The Effect of Structured Relapse Prevention Planning on Attitudes to Recovery from Depression: a review of the literature and programme planning
More information2) Percentage of adult patients (aged 18 years or older) with a diagnosis of major depression or dysthymia and an
Quality ID #370 (NQF 0710): Depression Remission at Twelve Months National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention, Treatment, and Management of Mental Health
More informationDisability from depression: The public health challenge to primary care
Disability from depression: The public health challenge to primary care KATHRYN ROST Rost K. Disability from depression: The public health challenge to primary care. Nord J Psychiatry 2009;63:1721. Oslo.
More informationMaking an IMPACT on late-life depression. Partnering with primary care providers can double the effect of treatment
University of Massachusetts Boston From the SelectedWorks of Steven D Vannoy Fall September, 2006 Making an IMPACT on late-life depression. Partnering with primary care providers can double the effect
More informationDepression intervention via referral, education, and collaborative treatment (Project DIRECT): a pilot study
Executive summary of completed research Depression intervention via referral, education, and collaborative treatment (Project DIRECT): a pilot study Principal Investigator Jane McCusker, MD DrPH Co-investigators
More informationIdentifying Adult Mental Disorders with Existing Data Sources
Identifying Adult Mental Disorders with Existing Data Sources Mark Olfson, M.D., M.P.H. New York State Psychiatric Institute Columbia University New York, New York Everything that can be counted does not
More informationGUIDELINES ISSUED BY THE
THE PATIENT-PHYSICIAN RELATIONSHIP Discontinuation of Use and Switching of Antidepressants Influence of Patient-Physician Communication Scott A. Bull, PharmD X. Henry Hu, MD, MPH, PhD Enid M. Hunkeler,
More informationPhase 2 Measures of Depression Population
Phase 2 Measures of Depression Population Each Phase 2 depression team is required to track and report the core national measures (measures 1 through 4) along with the count of patients with depression
More informationORIGINAL ARTICLE. of patients with diabetes mellitus meet criteria for comorbid major depression. 1,2 Depression is a risk
ORIGINAL ARTICLE The Pathways Study A Randomized Trial of Collaborative Care in Patients With Diabetes and Depression Wayne J. Katon, MD; Michael Von Korff, ScD; Elizabeth H. B. Lin, MD, MPH; Greg Simon,
More informationcare physicians (4 8). As a result, government agencies, accrediting organizations for example, the National Committee for Quality Assurance and
Aligning Incentives in the Treatment of Depression in Primary Care With Evidence-Based Practice Richard G. Frank, Ph.D. Haiden A. Huskamp, Ph.D. Harold Alan Pincus, M.D. Deficits in the quality of treatment
More informationOnset and recurrence of depressive disorders: contributing factors
SUMMARY People with depressive disorders frequently come to see their general practitioner (GP) as these conditions are highly prevalent. In the Netherlands, 19% of the general population experiences a
More informationSupplementary Online Content
Supplementary Online Content Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia:
More informationThe Wellness Assessment: Global Distress and Indicators of Clinical Severity May 2010
The Wellness Assessment: Global Distress and Indicators of Clinical Severity May 2010 Background Research has shown that the integration of outcomes measurement into clinical practice is associated with
More informationThe impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients
General Hospital Psychiatry 26 (2004) 199 209 The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients David A. Adler, M.D. a,b,c, *, Kathleen M. Bungay, Pharm.D.
More informationUndertreatment of Panic Disorder in Primary Care: Role of Patient and Physician Characteristics
Undertreatment of Panic Disorder in Primary Care: Role of Patient and Physician Characteristics Peter Roy-Byrne, MD, Joan Russo, PhD, David C. Dugdale, MD, Daniel Lessler, MD, Deborah Cowley, MD, and Wayne
More information8. DEPRESSION 1. Eve A. Kerr, M.D., M.P.H. and Kenneth A. Clark, M.D., M.P.H.
8. DEPRESSION 1 Eve A. Kerr, M.D., M.P.H. and Kenneth A. Clark, M.D., M.P.H. We relied on the following sources to construct quality indicators for depression: the AHCPR Clinical Practice Guideline in
More informationKeywords: neurological disease; emotional disorder
202 Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside Park, A J Carson B Ringbauer M Sharpe Medical Neurology, University of C Warlow Psychological Medicine M Sharpe Clinical Neurology,
More informationMset, with some episodes clearly linked to environmental
Prevention of Relapse and Recurrence in Depression: The Role of Long-Term Pharmacotherapy and Psychotherapy Andrew A. Nierenberg, M.D.; Timothy J. Petersen, Ph.D.; and Jonathan E. Alpert, M.D. Major depressive
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationFollow-Up and Follow-Through of Depressed Patients in Primary Care: The Critical Missing Components of Quality Care
Follow-Up and Follow-Through of Depressed Patients in Primary Care: The Critical Missing Components of Quality Care Leif I. Solberg, MD, Michael A. Trangle, MD, and Arthur P. Wineman, MD Certainly we could
More informationDEPRESSION Eve A. Kerr, M.D., M.P.H.
- 111-8. DEPRESSION Eve A. Kerr, M.D., M.P.H. We relied on the following sources to construct quality indicators for depression in adult women: the AHCPR Clinical Practice in Primary Care (Volumes 1 and
More informationObsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care
Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,
More informationDEPRESSION 1 Eve Kerr, M.D., M.P.H.
- 141-7. DEPRESSION 1 Eve Kerr, M.D., M.P.H. We relied on the following sources to construct quality indicators for depression in adult women: the AHCPR Clinical Practice in Primary Care (Volumes 1 and
More informationReliability and validity of the International Spinal Cord Injury Basic Pain Data Set items as self-report measures
(2010) 48, 230 238 & 2010 International Society All rights reserved 1362-4393/10 $32.00 www.nature.com/sc ORIGINAL ARTICLE Reliability and validity of the International Injury Basic Pain Data Set items
More informationHow can you improve. Talk to your patients about side effects and how long treatment will take. For personal use only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Family Practice the journal of Charlotte Brown, PhD, Deena R. Battista, PhD Department of Psychiatry, of Medicine,
More informationCare management for depression and osteoarthritis pain in older primary care patients: a pilot study
University of Massachusetts Boston From the SelectedWorks of Steven D Vannoy Spring April 8, 2008 Care management for depression and osteoarthritis pain in older primary care patients: a pilot study Ju
More informationA Randomized Controlled Trial of In-Person and Telephone Cognitive Behavioral Therapy for Major Depression after Traumatic Brain Injury
A Randomized Controlled Trial of In-Person and Telephone Cognitive Behavioral Therapy for Major Depression after Traumatic Brain Injury Josh Dyer, PhD Department of Rehabilitation Medicine University of
More informationCognitive Behavioral Analysis System of Psychotherapy as a Maintenance Treatment for Chronic Depression
Journal of Consulting and Clinical Psychology Copyright 2004 by the American Psychological Association 2004, Vol. 72, No. 4, 681 688 0022-006X/04/$12.00 DOI: 10.1037/0022-006X.72.4.681 Cognitive Behavioral
More informationIMPACT Improving Mood Promoting Access to Collaborative Treatment
IMPACT Improving Mood Promoting Access to Collaborative Treatment for Late-Life Depression Funded by John A. Hartford Foundation, California HealthCare Foundation, Robert Wood Johnson Foundation, Hogg
More informationThe Value of Providing Collaborative Care Models For Treating Employees with Depression
The Value of Providing Collaborative Care Models For Treating Employees with Depression Summary Depression is one of the costliest health issues for employers because of its high prevalence and co-morbidity
More informationSelf-care is a cornerstone of diabetes management. Daily practice of. Effects of Enhanced Depression Treatment on Diabetes Self-Care
Effects of Enhanced Depression Treatment on Diabetes Self-Care Elizabeth H. B. Lin, MD, MPH 1 Wayne Katon, MD 2 Carolyn Rutter, PhD 1 Greg E. Simon, MD, MPH 1 Evette J. Ludman, PhD 1 Michael Von Korff,
More informationBackground. Population/Intervention(s)/Comparator/Outcome(s) (PICO) Duration of antipsychotic treatment in individuals with a first psychotic episode
updated 2012 Duration of antipsychotic treatment in individuals with a first psychotic episode Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug
More informationORIGINAL INVESTIGATION. Response, Partial Response, and Nonresponse in Primary Care Treatment of Depression
ORIGINAL INVESTIGATION Response, Partial Response, and Nonresponse in Primary Care Treatment of Depression Patricia K. Corey-Lisle, PhD, RN-CSP; Rowena Nash, BA, BS; Paul Stang, PhD; Ralph Swindle, PhD
More informationEvidence Based Collaborative Care. Natasha Cunningham, MD Duke Department of Psychiatry and Behavioral Health Psychiatry Grand Rounds 9/24/15
Evidence Based Collaborative Care Natasha Cunningham, MD Duke Department of Psychiatry and Behavioral Health Psychiatry Grand Rounds 9/24/15 Objectives Identify three components of evidence based collaborative
More informationManaging Depression as a Chronic Condition. D. Green MD TOH/Bruyere Shared Care Program
Managing Depression as a Chronic Condition D. Green MD TOH/Bruyere Shared Care Program None Financial disclosure Objectives To review key concepts relevant to understanding the course of depression To
More informationTelephone Cognitive Behavioral Therapy for Rural Latinos: A Randomized Pilot Study
Telephone Cognitive Behavioral Therapy for Rural Latinos: A Randomized Pilot Study Gino Aisenberg, PhD UW School of Social Work Megan Dwight Johnson, MD MPH RAND Corporation Daniela Golinelli,, PhD RAND
More informationIn the last few years, evidence for the efficacy of psychotherapy
Article Relapse Prevention in With Bipolar Disorder: Outcome After 2 Years Dominic H. Lam, Ph.D. Peter Hayward, Ph.D. Edward R. Watkins, Ph.D. Kim Wright, B.A. Pak Sham, Ph.D. Objective: In a previous
More informationClinical Guidelines for the Pharmacologic Treatment of Schizophrenia
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationThe Association of Comorbid Depression With Mortality in Patients With Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E The Association of Comorbid Depression With Mortality in Patients With Type 2 Diabetes WAYNE J. KATON, MD 1 CAROLYN RUTTER,
More informationSTAKEHOLDER BENEFIT FROM DEPRESSION DISEASE MANAGEMENT: DIFFERENCES BY RURALITY?
STAKEHOLDER BENEFIT FROM DEPRESSION DISEASE MANAGEMENT: DIFFERENCES BY RURALITY? Kathryn Rost, PhD Stanley Xu, PhD Fran Dong, MS L. Miriam Dickinson, PhD April 2008 Working Paper Western Interstate Commission
More informationAssessment in Integrated Care. J. Patrick Mooney, Ph.D.
Assessment in Integrated Care J. Patrick Mooney, Ph.D. Purpose of assessment in integrated care: Assessment provides feedback to promote individual and group learning and change. Physicians Mental health
More informationMethods for Computing Missing Item Response in Psychometric Scale Construction
American Journal of Biostatistics Original Research Paper Methods for Computing Missing Item Response in Psychometric Scale Construction Ohidul Islam Siddiqui Institute of Statistical Research and Training
More informationORIGINAL INVESTIGATION. A Brief Measure for Assessing Generalized Anxiety Disorder
ORIGINAL INVESTIGATION A Brief Measure for Assessing Generalized Anxiety Disorder The GAD-7 Robert L. Spitzer, MD; Kurt Kroenke, MD; Janet B. W. Williams, DSW; Bernd Löwe, MD, PhD Background: Generalized
More informationSupplementary Online Content
Supplementary Online Content Weitz ES, Hollon SD, Twisk J, et al. Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: an individual
More informationSupplementary Material
Supplementary Material Supplementary Table 1. Symptoms assessed, number of items assessed, scoring, and cut-off points for the psychiatric rating scales: Montgomery Åsberg Depression Rating Scale, Hamilton
More informationPersonality traits predict current and future functioning comparably for individuals with major depressive and personality disorders
Wesleyan University From the SelectedWorks of Charles A. Sanislow, Ph.D. March, 2007 Personality traits predict current and future functioning comparably for individuals with major depressive and personality
More informationDiagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample
Available online at www.sciencedirect.com Drug and Alcohol Dependence 96 (2008) 187 191 Short communication Diagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample Lara A.
More informationAPPENDIX 11: CASE IDENTIFICATION STUDY CHARACTERISTICS AND RISK OF BIAS TABLES
APPENDIX 11: CASE IDENTIFICATION STUDY CHARACTERISTICS AND RISK OF BIAS TABLES 1 Study characteristics table... 3 2 Methodology checklist: the QUADAS-2 tool for studies of diagnostic test accuracy... 4
More informationDepression is one of the most prevalent and treatable. The PHQ-9. Validity of a Brief Depression Severity Measure
The PHQ-9 Validity of a Brief Depression Severity Measure Kurt Kroenke, MD, Robert L. Spitzer, MD, Janet B. W. Williams, DSW OBJECTIVE: While considerable attention has focused on improving the detection
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationCollaborative Care Management of Late-Life Depression in the Primary Care Setting JAMA. 2002;288:
ORIGINAL CONTRIBUTION Collaborative Care Management of Late-Life Depression in the Primary Care Setting A Randomized Controlled Trial Jürgen Unützer, MD, MPH Wayne Katon, MD Christopher M. Callahan, MD
More informationMental disorders can be very. A Meta-Analysis of Labor Supply Effects of Interventions for Major Depressive Disorder
A Meta-Analysis of Labor Supply Effects of Interventions for Major Depressive Disorder Justin W. Timbie, B.A. Marcela Horvitz-Lennon, M.D., M.P.H. Richard G. Frank, Ph.D. Sharon-Lise T. Normand, Ph.D.
More informationORIGINAL ARTICLE. The Effects of Adherence to Antidepressant Treatment Guidelines on Relapse and Recurrence of Depression
ORIGINAL ARTICLE The Effects of Adherence to Antidepressant Treatment Guidelines on Relapse and Recurrence of Depression Catherine A. Melfi, PhD; Anita J. Chawla, PhD; Thomas W. Croghan, MD; Mark P. Hanna,
More informationCENTER OF EXCELLENCE MATERNAL AND CHILD MENTAL HEALTH (MCMH)
CENTER OF EXCELLENCE MATERNAL AND CHILD MENTAL HEALTH (MCMH) The infant and young child should experience a warm, intimate, and continuous relationship with his mother in which both find satisfaction and
More informationDepression: The Benefits of Early and Appropriate Treatment
REPORTS Depression: The Benefits of Early and Appropriate Treatment Aron Halfin, MD Abstract Depression has a profound impact on patient health, individual and family quality of life, activities of daily
More informationPSYCHOLOGICAL CHALLENGES OF DIABETICS
PSYCHOLOGICAL CHALLENGES OF DIABETICS Does Depression Correlate to Diabetic Foot Ulcer Outcomes? Garneisha Torrence, PGY-3 DVA Puget Sound Health Care System Disclosure No relevant financial or non-financial
More informationORIGINAL ARTICLE. Two-Year Effects of Quality Improvement Programs on Medication Management for Depression
ORIGINAL ARTICLE Two-Year Effects of Quality Improvement rograms on Medication Management for Depression Jürgen Unützer, MD, MH; Lisa Rubenstein, MD, MSH; Wayne J. Katon, MD; Lingqi Tang, hd; Naihua Duan,
More informationProceedings of the International Conference on RISK MANAGEMENT, ASSESSMENT and MITIGATION
COGNITIVE-BEHAVIOURAL THERAPY EFFICACY IN MAJOR DEPRESSION WITH ASSOCIATED AXIS II RISK FACTOR FOR NEGATIVE PROGNOSIS DANIEL VASILE*, OCTAVIAN VASILIU** *UMF Carol Davila Bucharest, ** Universitary Military
More informationEpidemiological and clinical studies consistently indicate that
Depression and Comorbid Illness in Elderly Primary Care Patients: Impact on Multiple Domains of Health Status and Well-being Polly Hitchcock Noël, PhD 1,2 John W. Williams Jr, MD, MHS 3,4 Jürgen Unützer,
More informationAdherence in A Schizophrenia:
Understanding and Diagnosing Bipolar Disorder Treatment Promoting for Bipolar Treatment Disorder Adherence in A Schizophrenia: Resource for Providers Engagement Strategies for Health Care Providers, Case
More informationThe underdiagnosis of depression and the need for
JGIM Blackwell Publishing, Ltd. POPULATIONS AT RISK Effectiveness of Screening and Treatment for Depression in Ambulatory Indigent Patients David Jarjoura, PhD, Ann Polen, RN, Med, Elizabeth Baum, MD,
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationORIGINAL INVESTIGATION. Clinical Predictors of Mental Disorders Among Medical Outpatients
ORIGINAL INVESTIGATION Clinical Predictors of Mental Disorders Among Medical Outpatients Jeffrey L. Jackson, MD, MPH; James S. Houston, BS; Steven R. Hanling, BS; Kenneth A. Terhaar, BS; Joon S. Yun, BS
More informationMEXICAN- AND ANGLO-AMERICANS IN CARDIO REHABILITATION: DO CULTURAL DIFFERENCES MAKE A DIFFERENCE?
MEXICAN- AND ANGLO-AMERICANS IN CARDIO REHABILITATION: DO CULTURAL DIFFERENCES MAKE A DIFFERENCE? Ada Wilkinson-Lee, Michael J. Rohrbaugh, Joshua Schoenfeld, and Varda Shoham University of Arizona National
More informationDisability and quality of life. Prevalence and Severity of Mental Health Related Disability and Relationship to Diagnosis
Prevalence and Severity of Mental Health Related Disability and Relationship to Diagnosis Kristy Sanderson, Ph.D. Gavin Andrews, M.D. Objective: Psychiatric disability has been defined largely from measures
More informationDepression, Self-Care, and Medication Adherence in Type 2 Diabetes: Relationships Across the Full Range of Symptom Severity
Diabetes Care In Press, published online May 29, 2007 Depression, Self-Care, and Medication Adherence in Type 2 Diabetes: Relationships Across the Full Range of Symptom Severity Received for publication
More informationAdequacy of antidepressant
Course of Antidepressant Treatment, Drug Type, and Prescriber s Specialty Kathleen A. Fairman, M.A. Wayne C. Drevets, M.D. Jerold J. Kreisman, M.D. Fred Teitelbaum, Ph.D. Objective: The study examined
More informationCare Team Training. Key Components of Collaborative Care. Collaborative Team Approach 4/21/2014 PCP. Core Program. New Roles. Psychiatric Consultant
Team Training Key Components of Collaborative Collaborative Team Approach Patient PCP Manager New Roles Core Program Psychiatric Consultant Behavioral Health Clinicians Additional Clinic Resources Substance,
More informationDefense mechanisms and symptom severity in panic disorder
ACTA BIOMED 2010; 81: 30-34 Mattioli 1885 O R I G I N A L A R T I C L E Defense mechanisms and symptom severity in panic disorder Marco Fario, Sonja Aprile, Chiara Cabrino, Carlo Maggini, Carlo Marchesi
More informationWebinar Agenda. Terminology. What Is It? How this fits for depression. Social Innovation Fund. Relapse Prevention Planning. Relapse Prevention
SIF Webinar: Relapse Prevention 3/11/15 Webinar Agenda Relapse Prevention Social Innovation Fund Relapse Prevention Planning Rita Haverkamp Lori Higa What it is Why it s important Common and best practices
More informationUniversity of Groningen
University of Groningen Are effects of depression management training for General Practitioners on patient outcomes mediated by improvements in the process of care? van Os, TWDP; van den Brink, Robertus;
More informationCorrespondence of Pediatric Inpatient Behavior Scale (PIBS) Scores with DSM Diagnosis and Problem Severity Ratings in a Referred Pediatric Sample
1 1999 Florida Conference on Child Health Psychology Gainesville, FL Correspondence of Pediatric Inpatient Behavior Scale (PIBS) Scores with DSM Diagnosis and Problem Severity Ratings in a Referred Pediatric
More informationA Pilot Study of Interpersonal Psychotherapy for Depressed Women with Breast Cancer
A Pilot Study of Interpersonal Psychotherapy for Depressed Women with Breast Cancer CARLOS BLANCO, M.D., Ph.D.* JOHN C. MARKOWITZ, M.D.* DAWN L. HERSHMAN, M.D., M.S.# JON A. LEVENSON, M.D.* SHUAI WANG,
More informationBroadcastMed Bipolar, Borderline, Both? Diagnostic/Formulation Issues in Mood and Personality Disorders
BroadcastMed Bipolar, Borderline, Both? Diagnostic/Formulation Issues in Mood and Personality Disorders BRIAN PALMER: Hi. My name is Brian Palmer. I'm a psychiatrist here at Mayo Clinic. Today, we'd like
More informationIDDT Fidelity Action Planning Guidelines
1a. Multidisciplinary Team IDDT Fidelity Action Planning Guidelines Definition: All clients targeted for IDDT receive care from a multidisciplinary team. A multi-disciplinary team consists of, in addition
More informationDepression Can it ever be cured?
Depression Can it ever be cured? Disability, Relapses, and the Effect of Treatment Presented by Dr Julian Parmegiani MB BS FRANZCP 1208/370 Pitt St Sydney NSW 2000 12 August 2008 Claims & Underwriting
More informationPSYCHOLOGICAL CHALLENGES OF DIABETICS
PSYCHOLOGICAL CHALLENGES OF DIABETICS Does Depression Correlate to Diabetic Foot Ulcer Outcomes? Garneisha M. Torrence, PGY-3 DVA Puget Sound Health Care System Diabetes Overview In the US 29.1 million
More informationRobert Heinssen, PhD, ABPP North Carolina Practice Improvement Collaborative North Carolina State University, Raleigh NC November 7, 2014
Robert Heinssen, PhD, ABPP North Carolina Practice Improvement Collaborative North Carolina State University, Raleigh NC November 7, 2014 Disclosures I have no personal financial relationships with commercial
More informationDeveloping bipolar disorder. A study among children of patients with bipolar disorder Hillegers, Manon Hubertine Johanna
University of Groningen Developing bipolar disorder. A study among children of patients with bipolar disorder Hillegers, Manon Hubertine Johanna IMPORTANT NOTE: You are advised to consult the publisher's
More informationHelp and Healing: Section 2: Treatment Planning. Treatment and Timelines. Depression Treatment Reference. Care Team Communication
Help and Healing: Resources for Depression Care and Recovery Section 2: Treatment Planning Treatment and Timelines Depression Treatment Reference Care Team Communication Provider Education Tool - Questions
More informationAre Anti depressants Effective in the Treatment of Depressed Patients Who Do Not Seek Psychotherapy?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Are Anti depressants Effective in the
More informationCOLLABORATIVE CARE FOR PERINATAL DEPRESSION IN SOCIOECONOMICALLY DISADVANTAGED WOMEN: A RANDOMIZED TRIAL
Research Article DEPRESSION AND ANXIETY 32:821 834 (2015) COLLABORATIVE CARE FOR PERINATAL DEPRESSION IN SOCIOECONOMICALLY DISADVANTAGED WOMEN: A RANDOMIZED TRIAL Nancy K. Grote, Ph.D., 1 Wayne J. Katon,
More informationAnxiety disorders in mothers and their children: prospective longitudinal community study
Anxiety disorders in mothers and their children: prospective longitudinal community study Andrea Schreier, Hans-Ulrich Wittchen, Michael Höfler and Roselind Lieb Summary The relationship between DSM IV
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationA comparison of diabetic complications and health care utilization in diabetic patients with and without
John A. Dufton, DC, MD, Wilson W. Li, BSc (Pharm), MD, Mieke Koehoorn, PhD A comparison of diabetic complications and health care utilization in diabetic patients with and without comorbid A Canadian cross-sectional
More informationThe Bypassing the Blues Trial: Telephone-Delivered Collaborative Care for Treating Post-CABG Depression
The Bypassing the Blues Trial: Telephone-Delivered Collaborative Care for Treating Post-CABG Depression www.bypassingtheblues.pitt.edu Bruce L. Rollman, MD, MPH Professor of Medicine, Psychiatry, and Clinical
More informationHubley Depression Scale for Older Adults (HDS-OA): Reliability, Validity, and a Comparison to the Geriatric Depression Scale
The University of British Columbia Hubley Depression Scale for Older Adults (HDS-OA): Reliability, Validity, and a Comparison to the Geriatric Depression Scale Sherrie L. Myers & Anita M. Hubley University
More informationKim L. Gratz Department of Psychiatry and Human Behavior University of Mississippi Medical Center (UMMC)
Efficacy of an Acceptance-based Emotion Regulation Group Therapy for Deliberate Self-Harm among Women with Borderline Personality Pathology: Randomized Controlled Trial and 9-month Follow-up Kim L. Gratz
More information